vs
ARK RESTAURANTS CORP（ARKR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ARK RESTAURANTS CORP的季度营收约是REGENXBIO Inc.的1.3倍（$40.7M vs $30.3M），ARK RESTAURANTS CORP净利率更高（2.2% vs -221.3%，领先223.5%），REGENXBIO Inc.同比增速更快（43.0% vs -9.4%），ARK RESTAURANTS CORP自由现金流更多（$-1.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -1.8%）
ARK餐饮集团在美国多州运营数十家不同定位的餐饮门店，覆盖休闲正餐、快休闲餐饮及高端精致料理赛道，提供美式家常餐、烧烤、海鲜及意式美食，服务当地社区居民及往来游客。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ARKR vs RGNX — 直观对比
营收规模更大
ARKR
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出52.4%
-9.4%
净利率更高
ARKR
高出223.5%
-221.3%
自由现金流更多
ARKR
多$51.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.7M | $30.3M |
| 净利润 | $896.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 2.7% | -190.0% |
| 净利率 | 2.2% | -221.3% |
| 营收同比 | -9.4% | 43.0% |
| 净利润同比 | -71.7% | -31.2% |
| 每股收益（稀释后） | $0.25 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARKRRGNX
| Q4 25 | $40.7M | $30.3M | ||
| Q3 25 | $37.3M | $29.7M | ||
| Q2 25 | $43.7M | $21.4M | ||
| Q1 25 | $39.7M | $89.0M | ||
| Q4 24 | $45.0M | $21.2M | ||
| Q3 24 | $43.4M | $24.2M | ||
| Q2 24 | $50.4M | $22.3M | ||
| Q1 24 | $42.3M | $15.6M |
净利润ARKRRGNX
| Q4 25 | $896.0K | $-67.1M | ||
| Q3 25 | $-1.9M | $-61.9M | ||
| Q2 25 | $-3.5M | $-70.9M | ||
| Q1 25 | $-9.3M | $6.1M | ||
| Q4 24 | $3.2M | $-51.2M | ||
| Q3 24 | $-4.5M | $-59.6M | ||
| Q2 24 | $640.0K | $-53.0M | ||
| Q1 24 | $-1.4M | $-63.3M |
毛利率ARKRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ARKRRGNX
| Q4 25 | 2.7% | -190.0% | ||
| Q3 25 | -4.6% | -176.3% | ||
| Q2 25 | -7.8% | -296.3% | ||
| Q1 25 | -11.6% | 13.6% | ||
| Q4 24 | 12.6% | -242.1% | ||
| Q3 24 | -12.7% | -256.6% | ||
| Q2 24 | 1.6% | -251.3% | ||
| Q1 24 | -2.8% | -408.8% |
净利率ARKRRGNX
| Q4 25 | 2.2% | -221.3% | ||
| Q3 25 | -5.1% | -208.3% | ||
| Q2 25 | -7.9% | -331.8% | ||
| Q1 25 | -23.3% | 6.8% | ||
| Q4 24 | 7.0% | -241.3% | ||
| Q3 24 | -10.3% | -246.3% | ||
| Q2 24 | 1.3% | -237.7% | ||
| Q1 24 | -3.4% | -405.4% |
每股收益（稀释后）ARKRRGNX
| Q4 25 | $0.25 | $-1.30 | ||
| Q3 25 | $-0.53 | $-1.20 | ||
| Q2 25 | $-0.96 | $-1.38 | ||
| Q1 25 | $-2.57 | $0.12 | ||
| Q4 24 | $0.88 | $-0.99 | ||
| Q3 24 | $-1.24 | $-1.17 | ||
| Q2 24 | $0.18 | $-1.05 | ||
| Q1 24 | $-0.40 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $33.7M | $102.7M |
| 总资产 | $130.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARKRRGNX
| Q4 25 | $9.1M | $230.1M | ||
| Q3 25 | $11.3M | $274.2M | ||
| Q2 25 | $12.3M | $323.3M | ||
| Q1 25 | $11.1M | $267.9M | ||
| Q4 24 | $13.1M | $234.7M | ||
| Q3 24 | $10.3M | $255.5M | ||
| Q2 24 | $11.5M | $290.4M | ||
| Q1 24 | $10.4M | $338.7M |
股东权益ARKRRGNX
| Q4 25 | $33.7M | $102.7M | ||
| Q3 25 | $32.7M | $161.5M | ||
| Q2 25 | $34.7M | $213.7M | ||
| Q1 25 | $38.1M | $274.2M | ||
| Q4 24 | $47.3M | $259.7M | ||
| Q3 24 | $44.1M | $301.4M | ||
| Q2 24 | $48.9M | $348.3M | ||
| Q1 24 | $49.7M | $390.7M |
总资产ARKRRGNX
| Q4 25 | $130.4M | $453.0M | ||
| Q3 25 | $133.5M | $525.2M | ||
| Q2 25 | $136.3M | $581.0M | ||
| Q1 25 | $141.9M | $490.9M | ||
| Q4 24 | $154.6M | $466.0M | ||
| Q3 24 | $156.0M | $519.1M | ||
| Q2 24 | $166.5M | $569.4M | ||
| Q1 24 | $169.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-550.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | -4.4% | -174.0% |
| 资本支出强度资本支出/营收 | 3.1% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.61× | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ARKRRGNX
| Q4 25 | $-550.0K | $-52.3M | ||
| Q3 25 | $633.0K | $-56.0M | ||
| Q2 25 | $1.9M | $-49.3M | ||
| Q1 25 | $612.0K | $33.6M | ||
| Q4 24 | $-1.3M | $-31.6M | ||
| Q3 24 | $728.0K | $-40.5M | ||
| Q2 24 | $3.2M | $-45.5M | ||
| Q1 24 | $208.0K | $-55.5M |
自由现金流ARKRRGNX
| Q4 25 | $-1.8M | $-52.8M | ||
| Q3 25 | $-989.0K | $-56.5M | ||
| Q2 25 | $1.2M | $-49.7M | ||
| Q1 25 | $290.0K | $32.6M | ||
| Q4 24 | $-2.0M | $-32.7M | ||
| Q3 24 | $-482.0K | $-40.9M | ||
| Q2 24 | $2.5M | $-46.0M | ||
| Q1 24 | $-148.0K | $-56.0M |
自由现金流率ARKRRGNX
| Q4 25 | -4.4% | -174.0% | ||
| Q3 25 | -2.6% | -189.9% | ||
| Q2 25 | 2.7% | -232.8% | ||
| Q1 25 | 0.7% | 36.6% | ||
| Q4 24 | -4.4% | -154.2% | ||
| Q3 24 | -1.1% | -168.9% | ||
| Q2 24 | 5.0% | -206.2% | ||
| Q1 24 | -0.4% | -358.5% |
资本支出强度ARKRRGNX
| Q4 25 | 3.1% | 1.7% | ||
| Q3 25 | 4.3% | 1.7% | ||
| Q2 25 | 1.5% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 1.4% | 5.1% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 1.2% | 2.1% | ||
| Q1 24 | 0.8% | 3.6% |
现金转化率ARKRRGNX
| Q4 25 | -0.61× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -0.43× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARKR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
